Essais thérapeutiques

Etude : Roscovitine
Type d'étude : Modulateur du CFTR
Titre : A Phase II, Dose Ranging, Multicenter, Double-blind, Placebo Controlled Study to Evaluate Safety and Effects of (R)-Roscovitine in Adults Subjects With Cystic Fibrosis, Carrying 2 Cystic Fibrosis Causing Mutations With at Least One F508del-CFTR Mutation and Chronically Infected With Pseudomonas Aeruginosa, a Study Involving 36 CF Patients (24 Treated, 12 Controls). ROSCO-CF.
Phase : 2
Promoteurs :
Study in France
Age : 18 Years and Older
Lien internet : https://clinicaltrials.gov/ct2/show/NCT02649751

Etude : VX-661 / Ivacaftor
Type d'étude : Modulateur du CFTR
Titre : A Phase 3, Open-label, Rollover Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation
Phase : 3
Promoteurs :

Age : 12 Years and Older
Lien internet : https://clinicaltrials.gov/ct2/show/NCT02565914

Etude : VX-661/ ivacaftor
Type d'étude : Modulateur du CFTR
Titre : A Phase 3, Randomized, Double-Blind, Ivacaftor-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation and a Second CFTR Allele With a Gating Defect That Is Clinically Demonstrated to be Ivacaftor Responsive
Phase : 3
Promoteurs :
Belgium : Leuven
Italy : Milan, Rome
UK: Belfast, Birmingham, Leeds, London
Age : 12 Years and Older
Lien internet : https://clinicaltrials.gov/ct2/show/NCT02412111

Etude : QR-010
Type d'étude : Modulateur du CFTR
Titre : Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of QR-010 in Subjects With Homozygous ΔF508 Cystic Fibrosiss
Phase : 1b
Promoteurs :

Age : 18 Years to 60 Years
Lien internet : https://clinicaltrials.gov/ct2/show/NCT02532764